{"id":2226,"date":"2022-06-27T00:00:00","date_gmt":"2022-06-27T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2226"},"modified":"2022-06-27T00:00:00","modified_gmt":"2022-06-27T00:00:00","slug":"a-centogene-anuncia-a-aprovacao-de-todas-as-resolucoes-pelos-acionistas-na-assembleia-geral-anual-de-2022","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pt\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\/","title":{"rendered":"A CENTOGENE anuncia a aprova\u00e7\u00e3o de todas as resolu\u00e7\u00f5es pelos acionistas na Assembleia Geral Anual de 2022."},"content":{"rendered":"<p><strong>CAMBRIDGE, Massachusetts, ROSTOCK, Alemanha e BERLIM, 27 de junho de 2022 \u2013 <\/strong>A Centogene NV (Nasdaq: CNTG), parceira essencial em biodados para o setor de ci\u00eancias da vida em est\u00e1gio comercial, com foco em doen\u00e7as raras e neurodegenerativas, anunciou hoje os resultados da vota\u00e7\u00e3o em sua Assembleia Geral Anual. Os acionistas votaram a favor de todas as propostas, incluindo a nomea\u00e7\u00e3o de Miguel Coego Rios como Diretor-Geral e Diretor Financeiro.<\/p>\n<p>Os acionistas aprovaram as demonstra\u00e7\u00f5es financeiras anuais holandesas referentes ao exerc\u00edcio social encerrado em 31 de dezembro de 2021 e aprovaram a exonera\u00e7\u00e3o de responsabilidade dos membros dos Conselhos de Administra\u00e7\u00e3o e Fiscaliza\u00e7\u00e3o em rela\u00e7\u00e3o ao exerc\u00edcio social de 2021. Tamb\u00e9m foi aprovada a nomea\u00e7\u00e3o de Miguel Coego Rios como Diretor-Geral e Diretor Financeiro da Companhia. Al\u00e9m disso, os acionistas aprovaram as delibera\u00e7\u00f5es sobre a remunera\u00e7\u00e3o do Conselho Fiscal e prorrogaram a autoriza\u00e7\u00e3o para que o Conselho de Administra\u00e7\u00e3o da Companhia emita a\u00e7\u00f5es e outorgue direitos de subscri\u00e7\u00e3o de a\u00e7\u00f5es, limite e exclua direitos de prefer\u00eancia e adquira a\u00e7\u00f5es e recibos de dep\u00f3sito de a\u00e7\u00f5es do capital social da Companhia.<\/p>\n<p>Peer Schatz, Presidente do Conselho de Supervis\u00e3o da CENTOGENE, afirmou: \u201cGostar\u00edamos de agradecer aos nossos acionistas pelo apoio cont\u00ednuo \u00e0 miss\u00e3o da empresa. A CENTOGENE est\u00e1 possibilitando um impacto positivo e significativo na redu\u00e7\u00e3o do fardo das doen\u00e7as raras e neurodegenerativas para os pacientes, suas fam\u00edlias e a sociedade em geral. \u00c0 medida que emergimos da pandemia muito mais fortes, com uma estrat\u00e9gia refinada e uma equipe s\u00f3lida, acreditamos que temos uma grande oportunidade pela frente para cumprir nossa miss\u00e3o e gerar valor substancial para todas as partes interessadas.\u201d<\/p>\n<p>Na Assembleia Geral Ordin\u00e1ria de 2022 da CENTOGENE, estiveram representados 56,4% do capital social emitido da Companhia.<\/p>\n<h3>Sobre a CENTOGENE<\/h3>\n<p>A CENTOGENE dedica-se ao diagn\u00f3stico e \u00e0 pesquisa de doen\u00e7as raras, transformando dados cl\u00ednicos, gen\u00e9ticos e multi\u00f4micos do mundo real para diagnosticar, compreender e tratar essas doen\u00e7as. Nosso objetivo \u00e9 trazer racionalidade \u00e0s decis\u00f5es de tratamento e acelerar o desenvolvimento de novos medicamentos \u00f3rf\u00e3os, utilizando nosso amplo conhecimento e dados sobre doen\u00e7as raras. A CENTOGENE desenvolveu uma plataforma global propriet\u00e1ria para doen\u00e7as raras, baseada em nosso reposit\u00f3rio de dados do mundo real com mais de 650.000 indiv\u00edduos representando mais de 120 pa\u00edses diferentes.<\/p>\n<p>A plataforma da empresa inclui dados epidemiol\u00f3gicos, fenot\u00edpicos e gen\u00e9ticos que refletem uma popula\u00e7\u00e3o global, bem como um biobanco de amostras de sangue e culturas de c\u00e9lulas de pacientes. A CENTOGENE acredita que esta \u00e9 a \u00fanica plataforma focada na an\u00e1lise abrangente de dados em m\u00faltiplos n\u00edveis para aprimorar a compreens\u00e3o de doen\u00e7as heredit\u00e1rias raras. Ela permite uma melhor identifica\u00e7\u00e3o e estratifica\u00e7\u00e3o de pacientes e suas doen\u00e7as subjacentes, possibilitando e acelerando a descoberta, o desenvolvimento e o acesso a medicamentos \u00f3rf\u00e3os. Em 31 de dezembro de 2021, a empresa colaborava com mais de 30 parceiros farmac\u00eauticos.<\/p>\n<p>Siga-nos em <a href=\"https:\/\/de.linkedin.com\/company\/centogene\" title=\"Siga-nos no LinkedIn\">LinkedIn<\/a>.<\/p>\n<h3>Declara\u00e7\u00f5es prospectivas<\/h3>\n<p>Este comunicado de imprensa cont\u00e9m &quot;declara\u00e7\u00f5es prospectivas&quot; conforme definido pelas leis federais de valores mobili\u00e1rios dos EUA. Declara\u00e7\u00f5es aqui contidas que n\u00e3o sejam claramente de natureza hist\u00f3rica s\u00e3o prospectivas, e palavras como &quot;antecipar&quot;, &quot;acreditar&quot;, &quot;continuar&quot;, &quot;esperar&quot;, &quot;estimar&quot;, &quot;pretender&quot;, &quot;projetar&quot; e express\u00f5es semelhantes, bem como verbos no futuro ou no condicional, como &quot;ir\u00e1&quot;, &quot;poderia&quot;, &quot;deveria&quot;, &quot;conseguiria&quot;, &quot;talvez&quot;, &quot;pode&quot; e &quot;pode&quot;, geralmente s\u00e3o utilizadas para identificar declara\u00e7\u00f5es prospectivas. Tais declara\u00e7\u00f5es prospectivas envolvem riscos conhecidos e desconhecidos, incertezas e outros fatores importantes que podem fazer com que os resultados, o desempenho ou as conquistas reais da CENTOGENE sejam materialmente diferentes de quaisquer resultados, desempenho ou conquistas futuros expressos ou impl\u00edcitos nas declara\u00e7\u00f5es prospectivas. Tais riscos e incertezas incluem, entre outros, condi\u00e7\u00f5es econ\u00f4micas e geopol\u00edticas negativas, instabilidade e volatilidade nos mercados financeiros mundiais, poss\u00edveis mudan\u00e7as na legisla\u00e7\u00e3o, regulamenta\u00e7\u00e3o e pol\u00edticas governamentais atuais e propostas, press\u00f5es decorrentes do aumento da concorr\u00eancia e consolida\u00e7\u00e3o em nosso setor, o custo e a incerteza da aprova\u00e7\u00e3o regulat\u00f3ria, inclusive da Food and Drug Administration (FDA) dos EUA, nossa depend\u00eancia de terceiros e parceiros de colabora\u00e7\u00e3o, incluindo nossa capacidade de gerenciar o crescimento e estabelecer novos relacionamentos com clientes, nossa depend\u00eancia do setor de doen\u00e7as raras, nossa capacidade de gerenciar a expans\u00e3o internacional, nossa depend\u00eancia de pessoal-chave, nossa depend\u00eancia da prote\u00e7\u00e3o da propriedade intelectual, flutua\u00e7\u00f5es em nossos resultados operacionais devido ao efeito das taxas de c\u00e2mbio, nossa capacidade de otimizar o uso do caixa, nossa necessidade de financiamento adicional ou outros fatores. Para obter mais informa\u00e7\u00f5es sobre os riscos e incertezas que podem fazer com que os resultados reais sejam diferentes daqueles expressos nessas declara\u00e7\u00f5es prospectivas, bem como sobre os riscos relacionados aos neg\u00f3cios da CENTOGENE em geral, consulte os fatores de risco da CENTOGENE descritos no Formul\u00e1rio 20-F da CENTOGENE, arquivado em 31 de mar\u00e7o de 2022 junto \u00e0 Comiss\u00e3o de Valores Mobili\u00e1rios dos EUA (a \u201cSEC\u201d), e em arquivamentos subsequentes junto \u00e0 SEC. Quaisquer declara\u00e7\u00f5es prospectivas contidas neste comunicado \u00e0 imprensa referem-se apenas \u00e0 data deste documento, e a CENTOGENE se isenta especificamente de qualquer obriga\u00e7\u00e3o de atualizar qualquer declara\u00e7\u00e3o prospectiva, seja como resultado de novas informa\u00e7\u00f5es, eventos futuros ou outros fatores.<\/p>\n<h4 class=\"h3\">Contato com a m\u00eddia<\/h4>\n<h5>CENTOGENE<\/h5>\n<p>Lennart Streibel<br \/> Rela\u00e7\u00f5es com Investidores<br \/> <a href=\"mailto:investor.relations@centogene.com\" title=\"Escreva um e-mail\">investor.relations(at)centogene(dot)com <\/a><\/p>\n<p>Ben Legg<br \/> Comunica\u00e7\u00e3o Corporativa<br \/> <a href=\"mailto:press@centogene.com\" title=\"Escreva um e-mail\">press(at)centogene(dot)com<\/a><\/p>\n<h5>Stern IR<\/h5>\n<p>Suzanne Messere<br \/> +1 (212) 698-8801<br \/> <a href=\"mailto:suzanne.messere@sternir.com\" title=\"Escreva um e-mail\">suzanne(ponto)messere(arroba)sternir(ponto)com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>A CENTOGENE anuncia a aprova\u00e7\u00e3o de todas as resolu\u00e7\u00f5es pelos acionistas na Assembleia Geral Anual de 2022.<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2226","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pt\/a-centogene-anuncia-a-aprovacao-de-todas-as-resolucoes-pelos-acionistas-na-assembleia-geral-anual-de-2022\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pt\/a-centogene-anuncia-a-aprovacao-de-todas-as-resolucoes-pelos-acionistas-na-assembleia-geral-anual-de-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-27T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting\",\"datePublished\":\"2022-06-27T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\\\/\"},\"wordCount\":809,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\\\/\",\"name\":\"CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2022-06-27T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pt\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE anuncia aprova\u00e7\u00e3o de todas as resolu\u00e7\u00f5es pelos acionistas na Assembleia Geral Ordin\u00e1ria de 2022 | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pt\/a-centogene-anuncia-a-aprovacao-de-todas-as-resolucoes-pelos-acionistas-na-assembleia-geral-anual-de-2022\/","og_locale":"pt_BR","og_type":"article","og_title":"CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting | CENTOGENE","og_description":"CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting","og_url":"https:\/\/www.centogene.com\/pt\/a-centogene-anuncia-a-aprovacao-de-todas-as-resolucoes-pelos-acionistas-na-assembleia-geral-anual-de-2022\/","og_site_name":"CENTOGENE","article_published_time":"2022-06-27T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"admincg","Est. tempo de leitura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting","datePublished":"2022-06-27T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\/"},"wordCount":809,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\/","url":"https:\/\/www.centogene.com\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\/","name":"CENTOGENE anuncia aprova\u00e7\u00e3o de todas as resolu\u00e7\u00f5es pelos acionistas na Assembleia Geral Ordin\u00e1ria de 2022 | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2022-06-27T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-announces-shareholder-approval-of-all-resolutions-at-2022-annual-general-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Orientando a Medicina de Precis\u00e3o","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pt\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts\/2226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/comments?post=2226"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts\/2226\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/media?parent=2226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/categories?post=2226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/tags?post=2226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}